Taken collectively, these studies demonstrated that antiandrogen therapy may be an effective means of treating women with AR-positive, radioresistant breast cancers and provides the preclinical rationale for initiation of early phase clinical trials of combination antiandrogens and radiotherapy for women with AR-positive, triple-negative breast cancer at high risk of local recurrence. This evidence concerns the gene AR and breast carcinoma.